Session » Abstracts: Pediatric Rheumatology – Clinical I: JIA

Date: Sunday, November 12, 2023

Time: 4:00PM-5:30PM

Meeting: ACR Convergence 2023

Abstract Number: 0829

Decreased History of Breastfeeding During Infancy in Juvenile Spondyloarthritis: A Case-Control Study

Abstract Number: 0830

The Upregulation of MAP Kinase Pathway Genes Is Associated with Poor Treatment Response to Tofacitinib in Polyarticular Course Juvenile Idiopathic Arthritis

Abstract Number: 0831

Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study

Abstract Number: 0832

Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry

Abstract Number: 0833

Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort

Abstract Number: 0834

Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.